An estrogen receptor genetic polymorphism and a history of spontaneous abortion ? Correlation in women with estrogen receptor positive breast cancer but not in women with estrogen receptor negative breast cancer or in women without cancer

1993 ◽  
Vol 26 (2) ◽  
pp. 175-180 ◽  
Author(s):  
Steven P. Lehrer ◽  
Rita K. Schmutzler ◽  
Jill M. Rabin ◽  
Beth S. Schachter
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Genetic Polymorphism ◽  
Spontaneous Abortion ◽  
Estrogen Receptor Positive ◽  
History Of ◽  
Estrogen Receptor Negative ◽  
Positive Breast Cancer

scholarly journals Long-Term Sleep Duration as a Risk Factor for Breast Cancer: Evidence from a Systematic Review and Dose-Response Meta-Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Chunyang Lu ◽  
Hao Sun ◽  
Jinyu Huang ◽  
Songcheng Yin ◽  
Wenbin Hou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Sleep Duration ◽  
Dose Response ◽  
Nonlinear Relationship ◽  
Increased Risk ◽  
Non Linear ◽  
Estrogen Receptor Positive ◽  
Estrogen Receptor Negative ◽  
Positive Breast Cancer

Sleep patterns have been associated with the development of cancers, although the association between sleep duration and breast cancer remains controversial. The purpose of our study was to explore the relationship between sleep duration and breast cancer risk. The PubMed and Web of Science databases were searched, and restricted cubic splines were used to explore the dose-response relationship. Data from 415,865 participants were derived from 10 studies. A J-shaped nonlinear trend was found between sleep duration and breast cancer incidence (Pnon-linear = 0.012); compared with the reference hours (6 h or 7 h), with increasing sleep hours, the risk of breast cancer increased (Ptrend = 0.028). Moreover, a nonlinear relationship was found between sleep duration and estrogen receptor-positive breast cancer (Pnon-linear = 0.013); the risk of estrogen receptor-positive breast cancer increased with increasing sleep hours compared to the reference hours (Ptrend = 0.024). However, no nonlinear relationship was found between sleep duration and estrogen receptor-negative breast cancer; the risk of estrogen receptor-negative breast cancer was 1.035 for every additional sleep hour. Compared to women with the reference number of sleep hours, women with a longer sleep duration might have a significantly increased risk of breast cancer, especially estrogen receptor-positive breast cancer.

scholarly journals Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10503-10503
Author(s):  
Nima Sharifi ◽  
Megan Lynn Kruse ◽  
Jeffrey McManus ◽  
Yoon-Mi Chung ◽  
Wei Wei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
General Population ◽  
Postmenopausal Breast Cancer ◽  
Genotype Frequency ◽  
Estrogen Receptor Positive ◽  
Endogenous Estrogen ◽  
Postmenopausal Estrogen ◽  
Estrogen Receptor Negative ◽  
Positive Breast Cancer

10503 Background: Genetic factors that contribute to endogenous estrogen synthesis and postmenopausal breast cancer risk are unknown. We set out to test the hypothesis that homozygous inheritance of the common 1245A→C missense-encoding polymorphism in HSD3B1, which is common (8-10%) in White populations, functionally adrenal permissive and increases synthesis of the aromatase substrate, androstenedione, is associated with postmenopausal estrogen receptor-positive breast cancer. Methods: A prospective single institution study of postmenopausal estrogen receptor-driven breast cancer for determination of HSD3B1 genotype, circulating steroid concentrations, and adrenal-permissive genotype frequency compared with the genotype frequency in the general population and in estrogen receptor-negative breast cancer. Validation was performed in 2 breast cancer genomic studies with estrogen receptor documentation. The primary outcome is the adrenal-permissive genotype frequency in postmenopausal estrogen receptor-positive breast cancer and the general population. Genotype comparisons were also done with postmenopausal estrogen receptor-negative breast cancer and the association with circulating adrenal androgen concentrations determined. Results: The prospective and validation studies had 199 and 1628 women, respectively. The adrenal-permissive genotype frequency in postmenopausal White women with estrogen-driven breast cancer in the prospective cohort was 17.5% (21/120) compared with 9.6% (429/4451) in the general population [p = 0.0077]. The adrenal-permissive genotype frequency for estrogen-driven postmenopausal breast cancer was validated using the Cambridge and TCGA genomic datasets together: 14.4% (56/389) compared with 6.0% (9/149) for estrogen receptor-negative breast cancer (p = 0.007) and the general population (p = 0.005). Circulating androstenedione concentration was significantly higher for women with the adrenal-permissive genotype compared with the other genotypes (p = 0.03). Conclusions: The adrenal-permissive genotype is associated with estrogen-driven postmenopausal breast cancer. These findings link genetic inheritance of endogenous estrogen exposure to estrogen-driven breast cancer and have broad implications for risk stratification, prevention, potential biomarkers for hormonal therapy response and possibly other clinical outcomes related to estrogen physiology in postmenopausal women.

Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women

2004 ◽  
Vol 210 (2) ◽  
pp. 197-203 ◽  
Author(s):  
Chikako Noma ◽  
Yasuo Miyoshi ◽  
Tetsuya Taguchi ◽  
Yasuhiro Tamaki ◽  
Shinzaburo Noguchi
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Genetic Polymorphism ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Japanese Women ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document